Opinion|Videos|October 19, 2026
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
Author(s)Jeff Goff, RPh, MS
Jeff Goff, RPh, MS, walks through how UPMC has operationalized IV iron therapy from screening through infusion, and outlines how his team approaches hypophosphatemia monitoring and patient selection in light of the FDA's boxed warning.
Advertisement
Episodes in this series
Jeff Goff, RPh, MS, walks through how UPMC has operationalized IV iron therapy from screening through infusion, and outlines how his team approaches hypophosphatemia monitoring and patient selection in light of the FDA's boxed warning.
Advertisement
Related to this article
Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.
Pharmacy students can create greater career optionality by viewing the PharmD as a professional platform rather than a predetermined job title.
FDA-approved capivasertib triplet improves rPFS in PTEN-deficient mCSPC; learn dosing, key drug interactions, and managing diarrhea, hyperglycemia, and rash.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
After initial breast cancer treatment, pharmacists can help patients navigate ongoing endocrine therapy, manage persistent adverse effects, and address medication concerns that affect long-term care.
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Finerenone in Heart Failure: Evidence and Practice a Year Later
3
Pelacarsen, Ziltivekimab Miss CV End Points: What to Know
4
Breast Cancer Treatment Ends, But The Medication Questions Don’t
5